Genenta Science S.p.A. entered into an At-The-Market (ATM) Sales Agreement on April 26, 2024, with Capital One Securities, Inc. and Virtu Americas LLC. This agreement allows the company to offer and sell American Depositary Shares (ADSs) for an aggregate offering price of up to $16,362,816.
The ATM offering provides Genenta with a flexible mechanism to raise capital as needed to support its ongoing research and development activities. As a clinical-stage biotechnology company, Genenta relies on such financing to fund its pipeline, including the development of its lead candidate, Temferon.
This financial move is essential for maintaining liquidity and advancing clinical trials, which are capital-intensive endeavors in the biotechnology sector. The ability to access capital through this facility helps ensure the continuity of Genenta's operational and clinical programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.